XML 45 R62.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions Acquisitions - Narrative (Details)
 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
May 03, 2012
AmniSure [Member]
USD ($)
Dec. 31, 2012
Intelligent Bio Systems, Inc. [Member]
USD ($)
Dec. 31, 2012
Cellestis [Member]
USD ($)
Dec. 31, 2011
Cellestis [Member]
USD ($)
Aug. 29, 2011
Cellestis [Member]
USD ($)
Jul. 12, 2011
Ipsogen [Member]
USD ($)
Jul. 12, 2011
Ipsogen [Member]
EUR (€)
Dec. 31, 2012
Ipsogen [Member]
USD ($)
Dec. 31, 2011
Ipsogen [Member]
USD ($)
Biomarker
Dec. 31, 2011
Cellestis and Ipsogen [Member]
USD ($)
Dec. 31, 2010
Cellestis and Ipsogen [Member]
USD ($)
Dec. 31, 2011
Series of Individually Immaterial Business Acquisitions [Member]
USD ($)
Dec. 31, 2010
ESE GmbH and IFP [Member]
USD ($)
Dec. 31, 2012
Developed Technology, Licenses, and Know How [Member]
Cellestis [Member]
USD ($)
Dec. 31, 2012
Developed Technology, Licenses, and Know How [Member]
Ipsogen [Member]
USD ($)
Dec. 31, 2012
Customer Relationships [Member]
Cellestis [Member]
USD ($)
May 03, 2012
Minimum [Member]
AmniSure [Member]
Dec. 31, 2012
Minimum [Member]
Intelligent Bio Systems, Inc. [Member]
Dec. 31, 2011
Minimum [Member]
Series of Individually Immaterial Business Acquisitions [Member]
May 03, 2012
Maximum [Member]
AmniSure [Member]
Dec. 31, 2012
Maximum [Member]
Intelligent Bio Systems, Inc. [Member]
Dec. 31, 2011
Maximum [Member]
Series of Individually Immaterial Business Acquisitions [Member]
Jul. 12, 2011
Ipsogen [Member]
USD ($)
Jul. 12, 2011
Ipsogen [Member]
EUR (€)
Dec. 31, 2011
First Milestone [Member]
Series of Individually Immaterial Business Acquisitions [Member]
USD ($)
Dec. 31, 2011
Second Milestone [Member]
Series of Individually Immaterial Business Acquisitions [Member]
USD ($)
Business Acquisition [Line Items]                                                          
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 10 years 4 months 24 days     9 years 6 months   9 years 11 months 15 days         10 years                                    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets, Noncurrent                     $ 9,000,000                                    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles                     300,000           300,000 8,100,000 6,200,000                    
Business Combination, Acquisition Related Costs 4,500,000           5,800,000         5,600,000                                  
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent           3,900,000         (2,800,000)                                    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets, Liabilities, Net           1,600,000                                              
Goodwill, Purchase Accounting Adjustments 70,034,000 (615,000)       12,000,000         14,600,000                                    
Fair value of contingent consideration 19,000,000     4,530,000 12,000,000                   6,900,000                            
Discount Rate Used To Derive Fair Value Of Milestone Payments Of Acquisition                                       0.70% 0.70%   2.00% 1.60%       1.70% 3.25%
Probability Used To Derive Accomplishment Of Milestones Of Acquisition                                         95.00% 90.00%   100.00% 100.00%        
Business Acquisition, Contingent Consideration, Potential Cash Payment       35,000,000 12,500,000                   44,000,000 8,100,000                       5,500,000 1,400,000
Payments to Acquire Businesses, Gross         31,200,000                                                
Amounts held in escrow in connection with acquisitions 7,521,000 7,026,000     5,200,000                   8,500,000 2,900,000                          
Payment of Contingent Consideration in a Business Combination 7,100,000                                                        
Cash consideration       101,415,000   372,452,000   372,500,000     57,436,000         22,700,000                          
Number of Biomarkers                       15                                  
Business Combination Step Acquisition Equity Interest in Acquiree Payment                 57,400,000 40,900,000 29,800,000                                    
Business Acquisition, Percentage of Voting Interests Acquired                 62.60% 62.60% 89.40%         100.00%                          
Fair value of remaining shares                     42,437,000                                    
Outstanding Shares and Other Equity Instruments, Fair Value                                                   99,900,000 70,200,000    
Net sales 1,254,456,000 1,169,747,000 1,087,431,000                   28,600,000                                
Net income attributable to the owners of QIAGEN N.V. 129,506,000 96,038,000 144,311,000                   1,700,000                                
Business Acquisition, Pro Forma Revenue                         1,213,500,000 1,140,200,000                              
Business Acquisition, Pro Forma Net Income (Loss)                         91,900,000 139,200,000                              
Business Acquisition, Pro Forma Earnings Per Share, Diluted                         $ 0.38 $ 0.58                              
Payments to Acquire Businesses, Net of Cash Acquired $ 131,997,000 $ 457,483,000 $ 36,985,000                       $ 47,900,000